Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration
Manjit S Mehat, Venki Sundaram, Caterina Ripamonti, Anthony G Robson, Alexander J Smith, Shyamanga Borooah, Martha Robinson, Adam N Rosenthal, William Innes, Richard G Weleber, Richard W J Lee, Michael Crossland, Gary S Rubin, Baljean Dhillon, David H W Steel, Eddy Anglade, Robert P Lanza, Robin R Ali, Michel Michaelides, James W B Bainbridge, Manjit S Mehat, Venki Sundaram, Caterina Ripamonti, Anthony G Robson, Alexander J Smith, Shyamanga Borooah, Martha Robinson, Adam N Rosenthal, William Innes, Richard G Weleber, Richard W J Lee, Michael Crossland, Gary S Rubin, Baljean Dhillon, David H W Steel, Eddy Anglade, Robert P Lanza, Robin R Ali, Michel Michaelides, James W B Bainbridge
Abstract
Purpose: Transplantation of human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells offers the potential for benefit in macular degeneration. Previous trials have reported improved visual acuity (VA), but lacked detailed analysis of retinal structure and function in the treated area.
Design: Phase 1/2 open-label dose-escalation trial to evaluate safety and potential efficacy (clinicaltrials.gov identifier, NCT01469832).
Participants: Twelve participants with advanced Stargardt disease (STGD1), the most common cause of macular degeneration in children and young adults.
Methods: Subretinal transplantation of up to 200 000 hESC-derived RPE cells with systemic immunosuppressive therapy for 13 weeks.
Main outcome measures: The primary end points were the safety and tolerability of hESC-derived RPE cell administration. We also investigated evidence of the survival of transplanted cells and measured retinal structure and function using microperimetry and spectral-domain OCT.
Results: Focal areas of subretinal hyperpigmentation developed in all participants in a dose-dependent manner in the recipient retina and persisted after withdrawal of systemic immunosuppression. We found no evidence of uncontrolled proliferation or inflammatory responses. Borderline improvements in best-corrected VA in 4 participants either were unsustained or were matched by a similar improvement in the untreated contralateral eye. Microperimetry demonstrated no evidence of benefit at 12 months in the 12 participants. In one instance at the highest dose, localized retinal thinning and reduced sensitivity in the area of hyperpigmentation suggested the potential for harm. Participant-reported quality of life using the 25-item National Eye Institute Visual Function Questionnaire indicated no significant change.
Conclusions: Subretinal hyperpigmentation is consistent with the survival of viable transplanted hESC-derived RPE cells, but may reflect released pigment in their absence. The findings demonstrate the value of detailed analysis of spatial correlation of retinal structure and function in determining with appropriate sensitivity the impact of cell transplantation and suggest that intervention in early stage of disease should be approached with caution. Given the slow rate of progressive degeneration at this advanced stage of disease, any protection against further deterioration may be evident only after a more extended period of observation.
Crown Copyright © 2018. Published by Elsevier Inc. All rights reserved.
Figures
References
- Allikmets R., Singh N., Sun H. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet. 1997;15:236–246.
- Illing M., Molday L.L., Molday R.S. The 220-kDa rim protein of retinal rod outer segments is a member of the ABC transporter superfamily. J Biol Chem. 1997;272:10303–10310.
- Molday R.S., Zhong M., Quazi F. The role of the photoreceptor ABC transporter ABCA4 in lipid transport and Stargardt macular degeneration. Biochim Biophys Acta. 2009;1791:573–583.
- McBain V.A., Townend J., Lois N. Progression of retinal pigment epithelial atrophy in Stargardt disease. Am J Ophthalmol. 2012;154:146–154.
- Sparrow J.R., Hicks D., Hamel C.P. The retinal pigment epithelium in health and disease. Curr Mol Med. 2010;10:802–823.
- Lund R.D., Wang S., Klimanskaya I. Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats. Cloning Stem Cells. 2006;8:189–199.
- Lu B., Malcuit C., Wang S. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells. 2009;27:2126–2135.
- Schwartz S.D., Hubschman J.P., Heilwell G. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379:713–720.
- Schwartz S.D., Regillo C.D., Lam B.L. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385:509–516.
- Song W.K., Park K.M., Kim H.J. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Reports. 2015;4:860–872.
- Fujinami K., Lois N., Davidson A.E. A longitudinal study of Stargardt disease: clinical and electrophysiologic assessment, progression, and genotype correlations. Am J Ophthalmol. 2013;155:1075–1088.e13.
- Bland J.M., Altman D.G. Measurement error. BMJ. 1996;312:1654.
- Weleber R.G., Smith T.B., Peters D. VFMA: topographic analysis of sensitivity data from full-field static perimetry. Transl Vis Sci Technol. 2015;4:14.
- Tanna P., Strauss R.W., Fujinami K., Michaelides M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2017;101:25–30.
- McKay D.L. Congenital hypertrophy of the retinal pigment epithelium and familial adenomatous polyposis. Aust N Z J Ophthalmol. 1993;21:3–6.
- Carr A.J., Vugler A.A., Hikita S.T. Protective effects of human iPS-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat. PloS One. 2009;4:e8152.
- Engelhardt M., Tosha C., Lopes V.S. Functional and morphological analysis of the subretinal injection of retinal pigment epithelium cells. Vis Neurosci. 2012;29:83–93.
- Abercrombie M. Contact inhibition: the phenomenon and its biological implications. Natl Cancer Inst Monogr. 1967;26:249–277.
- Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124:619–626.
- Lopez R., Gouras P., Brittis M., Kjeldbye H. Transplantation of cultured rabbit retinal epithelium to rabbit retina using a closed-eye method. Invest Ophthalmol Vis Sci. 1987;28:1131–1137.
- Grisanti S., Szurman P., Jordan J. Xenotransplantation of retinal pigment epithelial cells into RCS rats. Jpn J Ophthalmol. 2002;46:36–44.
- Mandai M., Watanabe A., Kurimoto Y. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376:1038–1046.
- Kuriyan A.E., Albini T.A., Townsend J.H. Vision loss after intravitreal injection of autologous “stem cells” for AMD. N Engl J Med. 2017;376:1047–1053.
Source: PubMed